![](/img/cover-not-exists.png)
Dose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial
Yuen, M.-F., Elkashab, M., Chen, C.-Y., Coffin, C., Fung, S., Greenbloom, S., Jang, J.W., Jeng, R.W.-J., Kim, D.J., Kim, Y.J., Kim, W., Lee, K.S., Lim, Y.-S., Ramji, A., Iyer, R., Macfarlane, C., JackVolume:
68
Language:
english
Journal:
Journal of Hepatology
DOI:
10.1016/S0168-8278(18)31267-4
Date:
April, 2018
File:
PDF, 134 KB
english, 2018